A three-year-old boy named Oliver Chu made medical history by becoming the world’s first patient to receive a groundbreaking gene therapy for Hunter syndrome, a rare inherited disorder that can damage the body and brain. Experts describe the early signs as deeply hopeful, and his family from California have watched a life-altering process unfold at Royal Manchester Children’s Hospital in the UK, with five boys worldwide now in the trial.
Hunter syndrome, or MPS II, stems from a faulty IDS gene that leaves cells unable to produce an enzyme needed to break down large sugar molecules. Existing treatment with Elaprase slows physical symptoms but cannot reach the brain, leaving cognitive decline untreated and costly at around £300,000 per patient per year. The new approach uses a patient’s own stem cells, modified with the missing IDS gene, delivered via a virus that has its disease-causing potential removed. The goal is for these cells to repopulate the bone marrow and produce the enzyme throughout the body and, crucially, cross the blood-brain barrier to help the brain as well.
Oliver’s cells were collected and sent to Great Ormond Street Hospital in London for editing, then returned to Manchester for infusion. The treatment involved two separate infusions, and a year after starting the protocol, Oliver is reported to be developing normally. His family has witnessed noticeable improvements in mobility, speech, and engagement, leading to Oliver no longer needing weekly enzyme infusions as his body begins to produce the enzyme itself. Professor Simon Jones, who co-led the trial, said he had waited 20 years to see a patient like Ollie doing as well as he is, and Jingru, Oliver’s mother, added that each update brings tears of relief and joy: “Every time we talk about it I want to cry because it’s just so amazing.”
The study, organized by researchers at the University of Manchester with support from LifeArc, began after initial funding challenges nearly halted progress. LifeArc contributed £2.5 million to keep the trial alive, a pivotal moment that helped sustain the world-first effort. Oliver’s case is closely watched as researchers hope the same approach can be extended to other MPS types, including Hurler syndrome (MPS I) and Sanfilippo syndrome (MPS III).
Looking ahead, Oliver remains under strict follow-up for at least two years, with ongoing monitoring to confirm durability and safety. While the early results are encouraging, clinicians caution against over-interpretation and stress the need for longer-term data. The five-strong cohort spans the US, Europe, and Australia, with UK patients not eligible due to timing, yet researchers remain hopeful that broader access will follow if results hold. The team’s work also underscores a broader promise: applying this gene-therapy framework to other genetic disorders that affect both body and brain.